Browsing Tag
SYFOVRE
2 posts
Ocugen pairs OCU410 regulatory progress with a $130m balance-sheet reset
OCU410 gains FDA RMAT status as Ocugen prepares a 300-patient Phase 3 trial and funds development with convertible debt.
Apellis Pharmaceuticals gains 6.66% as investors bet on Q2 trial update and long-term pipeline potential
Apellis Pharmaceuticals stock jumped 6.66% as investors bet on key trial updates and undervalued biotech potential. Will FDA decisions drive more upside?